Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

DSpace/Manakin Repository

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

Citable link to this page

 

 
Title: Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
Author: Ning, Jianfang; Wakimoto, Hiroaki

Note: Order does not necessarily reflect citation order of authors.

Citation: Ning, Jianfang, and Hiroaki Wakimoto. 2014. “Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.” Frontiers in Microbiology 5 (1): 303. doi:10.3389/fmicb.2014.00303. http://dx.doi.org/10.3389/fmicb.2014.00303.
Full Text & Related Files:
Abstract: Oncolytic viruses (OV) are a class of antitumor agents that selectively kill tumor cells while sparing normal cells. Oncolytic herpes simplex virus (oHSV) has been investigated in clinical trials for patients with the malignant brain tumor glioblastoma for more than a decade. These clinical studies have shown the safety of oHSV administration to the human brain, however, therapeutic efficacy of oHSV as a single treatment remains unsatisfactory. Factors that could hamper the anti-glioblastoma efficacy of oHSV include: attenuated potency of oHSV due to deletion or mutation of viral genes involved in virulence, restricting viral replication and spread within the tumor; suboptimal oHSV delivery associated with intratumoral injection; virus infection-induced inflammatory and cellular immune responses which could inhibit oHSV replication and promote its clearance; lack of effective incorporation of oHSV into standard-of-care, and poor knowledge about the ability of oHSV to target glioblastoma stem cells (GSCs). In an attempt to address these issues, recent research efforts have been directed at: (1) design of new engineered viruses to enhance potency, (2) better understanding of the role of the cellular immunity elicited by oHSV infection of tumors, (3) combinatorial strategies with different antitumor agents with a mechanistic rationale, (4) “armed” viruses expressing therapeutic transgenes, (5) use of GSC-derived models in oHSV evaluation, and (6) combinations of these. In this review, we will describe the current status of oHSV clinical trials for glioblastoma, and discuss recent research advances and future directions toward successful oHSV-based therapy of glioblastoma.
Published Version: doi:10.3389/fmicb.2014.00303
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064532/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717576
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters